♤ India has said no to e-commerce negotiations at the WTO and any difference in its stance at the RCEP is likely to have repercussions.

♤ RCEP has been criticized by global and Indian health activists for potentially forcing India to end its cheap supply of drugs, specially related to HIV/AIDS to developing countries, especially Africa. India has to be wary of measures that may lead to its losing the right to produce cheap generic drugs due to the enforcement of a strict IPR regime related to patent term extension and data exclusivity.